

# Guideline: Venous Thromboembolism Prophylaxis Pharmacologic Recommendations, Adult, INPATIENT

Updated: April 19, 2022

## VTE Prophylaxis Pharmacologic Recommendations

*\*This is only a guideline. Please continue to use clinical judgement when verifying or ordering VTE prophylaxis medications.\**

Patient type with CrCl 30 mL/min or higher unless otherwise noted	General recommendations (choose one)
<b>Medical patients or COVID-19</b> <ul style="list-style-type: none"> <li><b>Medical:</b> using Padua scoring tool resulting in score of 4 or higher</li> <li><b>COVID-19 patients:</b> Padua score does not matter. <b>COVID-19 are HIGH RISK</b></li> </ul>	<b>Enoxaparin 40 mg subQ q24h (preferred)</b> Heparin 5000 units subQ q8h
<b>Surgical patients</b> <ul style="list-style-type: none"> <li><i>Caprini scoring tool resulting in score of 3 or higher</i></li> </ul>	<b>Enoxaparin 40 mg subQ q24h (preferred)</b> Heparin 5000 units subQ q8h
<b>Ortho Joint Replacement (HIP &amp; KNEE)</b> <ul style="list-style-type: none"> <li><i>Caprini score does not matter, this group is always considered HIGH RISK</i></li> </ul>	<b>HIP:</b> <ul style="list-style-type: none"> <li>Enoxaparin 40 mg subQ q24h begin at 0900 POD 1 (to begin at least 2 hrs after epidural removal)</li> <li>Rivaroxaban 10 mg PO q24h to begin at 0900 POD 1 (the first dose should be given AT LEAST 6 hours after surgery once hemostasis has been established. The first should be given a minimum of six hours after removal of epidural catheter). Continue for 35 days.</li> <li>Warfarin [titrate to INR] PO qHS (okay with history HIT)</li> <li>Aspirin 81 mg PO q 12 hr (okay with history HIT)</li> <li>Aspirin 325 mg PO q 12 hr (okay with history HIT)</li> </ul> <b>KNEE:</b> <ul style="list-style-type: none"> <li>Enoxaparin 30 mg subQ q12h to begin at 0900 POD 1 (to begin at least 2 hrs after epidural removal)</li> <li>Rivaroxaban 10 mg PO q24h to begin at 0900 POD 1 (the first dose should be given AT LEAST 6 hours after surgery once hemostasis has been established. The first should be given a minimum of six hours after removal of epidural catheter). Continue for 12 days.</li> <li>Warfarin [titrate to INR] PO qHS (okay with history HIT)</li> <li>Aspirin 81 mg PO q 12h (okay with history HIT)</li> <li>Aspirin 325 mg PO q 12h (okay with history HIT)</li> </ul>
<b>Ortho Minor</b> <ul style="list-style-type: none"> <li><i>Caprini score does not matter, this group is always considered HIGH RISK</i></li> </ul>	Enoxaparin 40 mg subQ q24h Heparin 5000 units subQ q8h Aspirin 81 mg PO q 12h (okay with history HIT) Aspirin 325 mg PO q 12h (okay with history HIT)
<b>Ortho Hip Fracture</b>	Enoxaparin 30 mg subQ q12h Heparin 5000 units subQ q8h Warfarin [titrate to INR] PO qHS

<ul style="list-style-type: none"> <li>• <i>Caprini score does not matter, this group is always considered HIGH RISK</i></li> </ul>	Aspirin 81 mg PO q 12h (okay with history HIT) Aspirin 325 mg PO q 12h (okay with history HIT)
<b>Trauma, Spinal Cord and Burn</b> <ul style="list-style-type: none"> <li>• <i>Caprini score does not matter, this group is always considered HIGH RISK</i></li> </ul>	Enoxaparin 40 mg subQ q12h <ul style="list-style-type: none"> <li>• Patient has ALL of the following: NO spinal cord injury or TBI, weight is &gt;50 kg, Age 18-65, and CrCl &gt;60 mL/min</li> </ul> Enoxaparin 30 mg subQ q12h <ul style="list-style-type: none"> <li>• Patient has: Spinal cord injury, TBI, CrCl 30-60 mL/min, age &gt;65, or weight 45-50 kg</li> </ul> Enoxaparin 30 mg subQ q24h <ul style="list-style-type: none"> <li>• Patient weight is &lt;45 kg OR CrCl 10-30 mL/min</li> </ul> Heparin 5000 units subQ q8h <ul style="list-style-type: none"> <li>• Patient has End Stage Renal Disease, epidural in place, or CrCl &lt;10 ml/min</li> </ul>
<b>Bariatrics</b> <ul style="list-style-type: none"> <li>• <i>Caprini score does not matter, this group is always considered HIGH RISK</i></li> </ul>	*Doses are initiated POD1* Enoxaparin 30 mg subQ q12h OR Enoxaparin 40 mg subQ q12h Heparin 5000 units subQ q8h
<b>OB</b> <ul style="list-style-type: none"> <li>• <b>Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. <i>Am J Perinatol.</i> 2019 Jan;36(2):130-135.)</b></li> </ul>	SCDs needed on all Csection patients Enoxaparin <ul style="list-style-type: none"> <li>• 50-90 kg: 40mg subQ q24h</li> <li>• Less than 50kg: 30 mg subQ q 24h</li> <li>• Greater than 90 kg: 40mg subQ q 12h</li> </ul> Heparin <ul style="list-style-type: none"> <li>• First trimester: 5000 units subQ q12h</li> <li>• Second trimester: 7500 units subQ q 12h</li> <li>• Third trimester: 10,000 units subQ q 12h</li> </ul> If epidural: Use heparin
<b>Obesity (BMI ≥40 kg/m<sup>2</sup>)</b>	Enoxaparin 40 mg subQ every 12 hours Heparin 7500 units subQ every 8 hours Heparin 5000 units subQ every 8 hours
<b>Low body weight (&lt; 45 kg)</b>	Enoxaparin 30 mg subQ every 24 hours (anti-Xa monitoring may be a consideration) Heparin 5000 units subQ every 12 hours Heparin 5000 units subQ every 8 hours
<b>CrCl 11-29 mL/min</b>	Heparin 5000 units subQ every 8 hours OB: Heparin (see heparin dosing based on trimester in OB section above) <b>Ortho, Bariatrics, Spine-Surgery, COVID-19 Patients, Trauma, Spinal Cord or Burn Only:</b> Enoxaparin 30mg subQ every 24 hours Ortho joint replacement patients: may use warfarin or aspirin at doses noted in ortho joint replacement section
<b>CrCl 10 mL/min or less or Hemodialysis</b>	Heparin 5000 units subQ q8h OB: Heparin (see heparin dosing based on trimester in OB section above) Ortho joint replacement patients: may use warfarin or aspirin at doses noted in ortho joint replacement section
<b>Additional pearls:</b> <ul style="list-style-type: none"> <li>• Consider Fondaparinux 2.5mg subQ daily if patient has a history of HIT AND CrCl &gt; 30 mL/min AND weight &gt; 50 kg (FONDAPARINUX IS NOT FOR ACTIVE EPIDURAL PATIENTS)</li> <li>• <b>Heparin</b> should be the <b>only</b> option for patients with <b>active</b> epidurals, defer to anesthesia recommendations on <b>timing</b> of prophylaxis agents around <b>placement and removal of catheter</b></li> <li>• <b>Stroke:</b> HOLD all anticoagulants for 24 hours post-tPA administration</li> <li>• <b>Post craniotomy patients:</b> SCDs only until determination of VTE prophylaxis by neurosurgery.</li> </ul>	

## Clinical guideline summary

**CLINICAL GUIDELINE NAME:** Adult VTE Prophylaxis Pharmacologic Recommendations

**PATIENT POPULATION AND DIAGNOSIS:** Adult inpatients by patient type and risk category.

**APPLICABLE TO:** All Spectrum Health hospitals

**BRIEF DESCRIPTION:** VTE prophylaxis pharmacologic recommendations for inpatients categorized by patient type and risk assessment score.

**OVERSIGHT TEAM LEADER(S):** Stephanie Burdick MD, Brittany Hoyte PharmD

**OWNING EXPERT IMPROVEMENT TEAM (EIT):** VTE

**MANAGING CLINICAL PRACTICE COUNCIL (CPC):** Acute Health

**CPC APPROVAL DATE:** April 26, 2022

**OTHER TEAM(S) IMPACTED:** Pharmacy

**IMPLEMENTATION DATE:** April 27, 2022

**LAST REVISED:** April 19, 2022

**FOR MORE INFORMATION, CONTACT:** Brittany Hoyte, PharmD

## References:

- 1) COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [April, 22, 2022].
- 2) INSPIRATION Investigators, Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. *JAMA*. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
- 3) Patell R, Chiasakul T, Bauer E, Zwicker JI. Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. *Thromb Haemost*. 2021 Jan;121(1):76-85. doi: 10.1055/s-0040-1721664.

- 4) Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv.* 2019 Dec 10;3(23):3898-3944. doi: 10.1182/bloodadvances.2019000975.
- 5) Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *Blood Adv.* 2018 Nov 27;2(22):3198-3225. doi: 10.1182/bloodadvances.2018022954.
- 6) Nicholson M, Chan N, Bhagirath V, Ginsberg J. Prevention of Venous Thromboembolism in 2020 and Beyond. *J Clin Med.* 2020 Aug 1;9(8):2467. doi: 10.3390/jcm9082467.
- 7) Alsheikh K, Hilabi A, Aleid A, et al. Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery. *Cureus.* 2021 Nov 18;13(11):e19691. doi: 10.7759/cureus.19691.
- 8) Matharu GS, Kunutsor SK, Judge A, et al. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Intern Med.* 2020 Mar 1;180(3):376-384. doi: 10.1001/jamainternmed.2019.6108.
- 9) Ley EJ, Brown CVR, Moore EE, et al. Updated guidelines to reduce venous thromboembolism in trauma patients: A Western Trauma Association critical decisions algorithm. *J Trauma Acute Care Surg.* 2020 Nov;89(5):971-981. doi: 10.1097/TA.0000000000002830.
- 10) Sebaaly J, Covert K. Enoxaparin Dosing at Extremes of Weight: Literature Review and Dosing Recommendations. *Ann Pharmacother.* 2018 Sep;52(9):898-909. doi: 10.1177/1060028018768449.
- 11) Abildgaard A, Madsen SA, Hvas AM. Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. *Semin Thromb Hemost.* 2020 Nov;46(8):932-969. doi: 10.1055/s-0040-1718405.
- 12) Kolettis D, Craigo S. Thromboprophylaxis in Pregnancy. *Obstet Gynecol Clin North Am.* 2018 Jun;45(2):389-402. doi: 10.1016/j.ogc.2018.01.007.
- 13) Middleton P, Shepherd E, Gomersall JC. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period. *Cochrane Database Syst Rev.* 2021 Mar 29;3(3):CD001689. doi: 10.1002/14651858.CD001689.pub4.
- 14) Eubanks AA, Deering SH, Thiel LM. Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. *Am J Perinatol.* 2019 Jan;36(2):130-135. doi: 10.1055/s-0038-1672164.